Ipamorelin dosing in the research literature — third person, never a recommendation

The gist

This page lays out the ipamorelin doses that appear in published studies — and only those. It describes what researchers gave to rats, ferrets, swine, and a small number of human volunteers, by which route, and how long the peptide stuck around. It is not a how-to. Ipamorelin has never been approved as a medicine, there is no established human dose, and nothing here should be read as instructions. The numbers are study facts: a human pharmacokinetic trial, a failed Phase 2 trial, and a handful of animal experiments. Where community 'stack' protocols come up, we say plainly that they have no peer-reviewed human dosing basis. Think of this as a reference for understanding the research, not a protocol to follow.

Doses used in published studies

Across the literature, ipamorelin has been administered at very different exposures depending on the model:

• Human PK/PD study: 4.21 to 140.45 nmol/kg intravenously over 15 minutes, as single doses, in healthy male volunteers ^[2].
• Human Phase 2 ileus trial: 0.03 mg/kg intravenously twice daily for up to 7 days ^[3].
• Rat bone-growth study: 18, 90, and 450 micrograms per day subcutaneously, divided three times daily, for 15 days ^[4].
• Ferret cachexia study (2024): 1 to 3 mg/kg intraperitoneally ^[5].

These are research exposures in specific models, reported here for completeness. They are not interchangeable with one another and carry no implication for human use. The popular community practice of pairing ipamorelin with CJC-1295 in subcutaneous regimens has no peer-reviewed human dosing basis and is anecdotal, not recommended.

Half-life and how the body handles it

In healthy human volunteers, ipamorelin showed a terminal half-life of approximately 2 hours after intravenous dosing, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg ^[2]. The GH response is a single discrete pulse peaking about 40 minutes after dosing ^[2] — the peptide does its work quickly and then clears. In rats, plasma clearance is roughly five-fold lower than that of GHRP-6.

Routes studied span intravenous (human PK and clinical trials, plus rodent efficacy), subcutaneous (rodent bone and body-composition studies, and the dominant route in community use), intranasal (rodent PK, around 20% bioavailability), and intraperitoneal (rodent and ferret efficacy). Oral dosing applies only to engineered ipamorelin-derived analogs, which reached about 10% bioavailability in dogs ^[8] — ipamorelin itself is not orally bioavailable.

How much cjc-1295 ipamorelin should i take

There is no answer to this question that this site can responsibly give, because no validated human dose exists. The phrase 'how much cjc-1295 ipamorelin should i take' is among the most-searched ipamorelin queries, but the honest position is that neither ipamorelin nor the CJC-1295 combination has an approved human dose or a controlled-trial dosing basis ^[3]. Published ipamorelin doses are research exposures in animals and a small number of human volunteers ^[2][4], not personal regimens. Community stack protocols circulate widely but rest on anecdote, not peer-reviewed human data — and ipamorelin is also prohibited in sport at all times under WADA category S2.

How to reconstitute cjc-1295 ipamorelin 5mg

Ipamorelin is supplied as a lyophilized (freeze-dried) powder — free base or acetate salt — that is reconstituted with bacteriostatic water for research handling ^[2]. As a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations drawn from the research-supply literature, not a clinical preparation instruction and not a dosing protocol. This site does not provide reconstitution recipes or volumes for human use; the question 'how to reconstitute cjc-1295 ipamorelin 5mg' is a handling query, and the only defensible answer is the general stability context above. There is no approved human preparation of either peptide.

Stability and handling notes

The handling profile is the standard one for a research peptide. Ipamorelin's lyophilized powder is stable in storage but, once reconstituted, is subject to degradation by heat and repeated freeze-thaw cycles ^[2]. Researchers typically refrigerate reconstituted material. None of this constitutes a preparation or administration instruction for humans — it is descriptive context for how the molecule behaves as a peptide, included so the research record is complete.